Lipid Metabolism Practice Questions

Q: Hypertriglyceridemia is not a feature of which of the following conditions?

Alcoholism. **Explanation:** This question appears to have a technical error in its framing or key, as **Alcoholism, Obesity, Diabetes Mellitus, and Pregnancy are all classic causes of Hypertriglyceridemia.** However, in the context of standard medical examinations, if one must be excluded based on the *primary* lipid profile change or the *mechanism* of lipid elevation, the reasoning is as follows: 1. **Alcoholism (Correct Answer per key):** While chronic alcohol consumption typically **increases** VLDL and triglycerides (by increasing the NADH/NAD+ ratio, which promotes fatty acid synthesis), some examiners argue that its hallmark is fatty liver (steatosis) rather than isolated systemic hypertriglyceridemia, or they may be contrasting it with the more "direct" metabolic syndromes. *Note: Clinically, alcohol is a major cause of Type IV hyperlipidemia.* 2. **Obesity:** Strongly associated with hypertriglyceridemia. Increased adipose tissue leads to higher flux of free fatty acids to the liver, stimulating VLDL production. 3. **Diabetes Mellitus:** Insulin deficiency or resistance decreases the activity of **Lipoprotein Lipase (LPL)**. Since LPL is required to clear chylomicrons and VLDL, its deficiency leads to significant hypertriglyceridemia. 4. **Pregnancy:** A physiological state of hyperlipidemia. Estrogen increases VLDL synthesis, and insulin resistance in the third trimester decreases LPL activity to ensure nutrient availability for the fetus. **High-Yield Clinical Pearls for NEET-PG:** * **LPL Activator:** Insulin and Apo C-II. * **LPL Inhibitor:** Apo C-III and Angiopoietin-like protein 4. * **Eruptive Xanthomas:** Characteristic skin finding when serum triglycerides exceed 1000 mg/dL. * **Acute Pancreatitis:** A critical complication of severe hypertriglyceridemia. * **Alcohol's effect:** Increases NADH, leading to increased alpha-glycerophosphate, which provides the backbone for triglyceride synthesis.

Q: Which one of the following is of highest predictive value in the morbidity of coronary heart disease?

Apolipoprotein B. **Explanation:** **Apolipoprotein B (ApoB)** is considered the most accurate predictor of coronary heart disease (CHD) risk because it provides a direct measure of the total number of atherogenic particles. Each particle of VLDL, IDL, and LDL contains exactly **one molecule of ApoB-100**. While LDL-C measures the cholesterol *volume* within particles (which can vary), ApoB reflects the actual *particle count*. Since smaller, denser LDL particles are more prone to oxidation and arterial wall penetration, a high ApoB count indicates a higher "atherogenic burden," even if total LDL-C levels appear normal. **Analysis of Incorrect Options:** * **Low-Density Lipoprotein (LDL):** While traditionally used as the primary target for therapy, LDL-C can be misleading in patients with metabolic syndrome or diabetes who have small, dense LDL particles. ApoB has been shown in recent trials (like the INTERHEART study) to be a superior predictor compared to LDL-C. * **Lipoprotein (a) [Lp(a)]:** This is an independent genetic risk factor for CHD. While highly significant, it is not as strong a universal predictor of morbidity as the total ApoB count. * **Apolipoprotein A (ApoA-1):** This is the primary protein associated with HDL (the "good" cholesterol). A *low* level of ApoA-1 is associated with risk, but it is the **ApoB/ApoA-1 ratio** (rather than ApoA alone) that is a strong predictor. **High-Yield Clinical Pearls for NEET-PG:** * **ApoB-100** is found in VLDL, IDL, and LDL (liver-derived). * **ApoB-48** is found in Chylomicrons (intestine-derived). * **Friedewald Formula:** LDL = Total Cholesterol – [HDL + (Triglycerides/5)]. This formula is invalid if TG >400 mg/dL. * **ApoB/ApoA-1 ratio** is often cited as the single most important lipid parameter for predicting myocardial infarction risk.

Q: All of the following statements about fatty acid synthesis are true, except:

Palmitoleic acid is the end product. **Explanation:** The correct answer is **D**, as the primary end product of the fatty acid synthase (FAS) complex is **Palmitic acid (Palmitate)**, a 16-carbon saturated fatty acid. Palmitoleic acid is a monounsaturated fatty acid (16:1) formed later by desaturation in the endoplasmic reticulum. **Analysis of Options:** * **A. Occurs in cytosol:** This is true. Unlike fatty acid oxidation (which occurs in the mitochondria), synthesis takes place in the cytoplasm, primarily in the liver, lactating mammary glands, and adipose tissue. * **B. Citrate shuttle is required:** This is true. Acetyl CoA is produced in the mitochondria but cannot cross the inner mitochondrial membrane. It condenses with oxaloacetate to form **Citrate**, which is shuttled into the cytosol and cleaved back into Acetyl CoA and oxaloacetate by *ATP-citrate lyase*. * **C. Acetyl CoA is the immediate substrate:** This is true. Acetyl CoA serves as the initial primer and the building block (after conversion to Malonyl CoA) for the synthesis of the carbon chain. **High-Yield NEET-PG Pearls:** * **Rate-limiting enzyme:** Acetyl CoA Carboxylase (ACC), which requires **Biotin** (Vitamin B7) as a cofactor. * **Reductant:** **NADPH** is the essential electron donor, primarily supplied by the Hexose Monophosphate (HMP) Shunt. * **Multienzyme Complex:** In humans, Fatty Acid Synthase is a dimer with seven different catalytic activities on a single polypeptide chain, including the **Acyl Carrier Protein (ACP)** which contains Vitamin B5 (Pantothenic acid). * **Inhibitor:** Malonyl CoA inhibits *Carnitine Palmitoyltransferase-I (CPT-I)*, preventing simultaneous synthesis and degradation of fatty acids (preventing a futile cycle).

Q: Eicosapentaenoic acid is present in which of the following?

Fish oil. **Explanation:** **Eicosapentaenoic acid (EPA)** is a long-chain **Omega-3 (ω-3) polyunsaturated fatty acid (PUFA)** containing 20 carbons and five double bonds (20:5; Δ5,8,11,14,17). **Why Fish Oil is Correct:** The primary dietary sources of EPA and Docosahexaenoic acid (DHA) are **marine oils**, specifically fatty fish (e.g., salmon, mackerel, sardines) and fish oil supplements. These marine organisms accumulate EPA from the microalgae they consume. In humans, EPA serves as a precursor for **Series-3 prostaglandins** and **Series-5 leukotrienes**, which are generally anti-inflammatory and cardioprotective. **Why Other Options are Incorrect:** * **Soybean oil, Corn oil, and Safflower oil** are primarily rich in **Omega-6 (ω-6) fatty acids**, specifically **Linoleic acid** (18:2; Δ9,12). * While some plant oils (like flaxseed or soybean) contain the omega-3 fatty acid **Alpha-linolenic acid (ALA)**, the conversion of ALA to EPA in the human body is inefficient. Therefore, these oils are not considered direct sources of EPA. **High-Yield Clinical Pearls for NEET-PG:** * **Essential Fatty Acids (EFA):** Linoleic acid (ω-6) and Alpha-linolenic acid (ω-3) are "true" EFAs because humans lack the enzymes (Δ12 and Δ15 desaturases) to synthesize them. * **Cardiovascular Benefit:** EPA competes with Arachidonic acid for the enzyme Cyclooxygenase (COX). EPA produces **Thromboxane A3 (TXA3)**, which is a very weak platelet aggregator, thereby reducing the risk of intravascular thrombosis. * **DHA (22:6; ω-3):** Often found alongside EPA in fish oil; it is vital for retinal function and brain development in infants.

Q: Which of the following uses ketone bodies, except?

Hepatocytes. **Explanation:** The correct answer is **Hepatocytes (Option D)**. The utilization of ketone bodies (ketolysis) requires the enzyme **Thiophorase** (also known as Succinyl-CoA:3-ketoacid CoA transferase). While the liver is the primary site of **ketogenesis** (production of ketone bodies), it lacks the enzyme Thiophorase. Therefore, the liver can produce ketone bodies but cannot utilize them for energy, ensuring that ketone bodies are exported to peripheral tissues during starvation. **Analysis of other options:** * **Brain (Option A):** During prolonged starvation, the brain adapts to use ketone bodies (specifically 3-hydroxybutyrate and acetoacetate) as its primary energy source, meeting up to 75% of its energy requirements to spare glucose. * **RBCs (Option B):** This is a common point of confusion. **RBCs cannot use ketone bodies** because they lack mitochondria (ketolysis occurs in the mitochondrial matrix). However, in the context of this specific question, **Hepatocytes** is the most definitive answer regarding the specific absence of the enzyme Thiophorase. *Note: If both are options, Hepatocytes is the classical biochemical answer for "lack of enzyme."* * **Skeletal Muscles (Option C):** Extrahepatic tissues like skeletal and cardiac muscles are the primary consumers of ketone bodies during early starvation. **High-Yield Facts for NEET-PG:** 1. **Rate-limiting enzyme of Ketogenesis:** HMG-CoA Synthase (Mitochondrial). 2. **Organelle:** Ketogenesis and Ketolysis both occur in the **Mitochondria**. 3. **Ketone bodies:** Acetoacetate, 3-hydroxybutyrate, and Acetone (a non-metabolizable waste product). 4. **Key Deficiency:** Liver lacks **Thiophorase**, preventing a futile cycle.

Q: Hepatosplenomegaly with foam cells is characteristically seen in a lysosomal disorder. This disorder is due to the deficiency of which enzyme?

Sphingomyelinase. **Explanation:** The clinical presentation of **hepatosplenomegaly** combined with the presence of **foam cells** (lipid-laden macrophages) is the hallmark of **Niemann-Pick Disease (Types A and B)**. This autosomal recessive lysosomal storage disorder is caused by a deficiency of the enzyme **Sphingomyelinase**, leading to the accumulation of sphingomyelin within the lysosomes of the reticuloendothelial system. **Analysis of Options:** * **A. Sphingomyelinase (Correct):** Its deficiency leads to Niemann-Pick Disease. The characteristic "foam cells" are macrophages with a "mulberry" or soap-bubble appearance due to accumulated sphingomyelin. * **B. Hexosaminidase A:** Deficiency causes **Tay-Sachs Disease**. While it features a cherry-red spot on the macula, it is distinguished by the **absence** of hepatosplenomegaly. * **C. Beta-galactosidase:** Deficiency causes **Krabbé disease** (characterized by globoid cells and demyelination) or **GM1 gangliosidosis**. * **D. Beta-glucosidase (Glucocerebrosidase):** Deficiency causes **Gaucher Disease**. While it also presents with hepatosplenomegaly, the characteristic cells are **Gaucher cells** (described as "wrinkled tissue paper" or "crumpled silk" appearance), not foam cells. **NEET-PG High-Yield Pearls:** * **Niemann-Pick vs. Tay-Sachs:** Both can have a **cherry-red spot**, but only Niemann-Pick has **hepatosplenomegaly**. * **Mnemonic:** "No-man Picks (Niemann-Pick) his nose with his **Foamy** finger." * **Zebra Bodies:** Electron microscopy in Niemann-Pick shows lamellated cytosolic inclusions called zebra bodies. * **Type A vs. B:** Type A is the infantile, neuropathic form; Type B presents later with no CNS involvement.

Q: In the well-fed state, what inhibits the activity of Carnitine Palmitoyl Transferase-1 located in the outer mitochondrial membrane?

Malonyl-CoA. **Explanation:** The correct answer is **Malonyl-CoA**. This is a classic example of metabolic regulation designed to prevent a "futile cycle" (simultaneous synthesis and breakdown of fatty acids). **1. Why Malonyl-CoA is correct:** In the **well-fed state**, insulin levels are high, leading to increased fatty acid synthesis in the cytosol. The first committed step of lipogenesis is the conversion of Acetyl-CoA to Malonyl-CoA by the enzyme *Acetyl-CoA Carboxylase (ACC)*. **Malonyl-CoA** acts as a potent allosteric inhibitor of **Carnitine Palmitoyl Transferase-1 (CPT-1)**. By inhibiting CPT-1, Malonyl-CoA prevents the transport of long-chain fatty acids into the mitochondria for β-oxidation. This ensures that while the body is actively synthesizing fat, it is not simultaneously burning it. **2. Why other options are incorrect:** * **Glucose:** While high glucose levels trigger the insulin release that leads to Malonyl-CoA production, glucose itself does not directly bind to or inhibit CPT-1. * **Acetyl-CoA:** This is a precursor for both the TCA cycle and lipogenesis. While it is used to form Malonyl-CoA, it does not directly inhibit CPT-1. * **Pyruvate:** Pyruvate is the end-product of glycolysis. It enters the mitochondria to be converted into Acetyl-CoA but has no direct regulatory effect on the carnitine shuttle. **High-Yield Clinical Pearls for NEET-PG:** * **CPT-1 Location:** It is located on the **outer** mitochondrial membrane, whereas CPT-2 is on the inner membrane. * **Rate-Limiting Step:** CPT-1 is the rate-limiting step for **β-oxidation** of fatty acids. * **Deficiency:** CPT-1 deficiency typically presents as non-ketotic hypoglycemia and hepatomegaly, often triggered by fasting. * **Key Concept:** Insulin → Stimulates ACC → ↑ Malonyl-CoA → Inhibits CPT-1 → ↓ Fatty acid oxidation.

Q: Lipoprotein X is most likely to be seen with which of the following conditions?

Cholestasis. **Explanation:** **Lipoprotein X (LpX)** is an abnormal, pathological lipoprotein that appears in the serum of patients with **cholestasis** (obstructive jaundice) or Lecithin-Cholesterol Acyltransferase (LCAT) deficiency. **Why Cholestasis is Correct:** In cholestasis, the normal biliary excretion of phospholipids and cholesterol is impaired. This leads to a "regurgitation" of biliary lipids into the plasma. These lipids, primarily unesterified cholesterol and lecithin, aggregate to form LpX. Unlike normal lipoproteins, LpX lacks Apolipoprotein B and is characterized by a high content of free cholesterol and phospholipids. It is considered a highly specific diagnostic marker for obstructive jaundice. **Why Incorrect Options are Wrong:** * **Gilbert Syndrome:** This is a benign condition characterized by unconjugated hyperbilirubinemia due to decreased bilirubin glucuronidation. It does not involve biliary obstruction or lipid regurgitation; hence, LpX is not formed. * **Trans Fatty Acids:** Increased intake of trans fats is associated with elevated LDL ("bad" cholesterol) and decreased HDL ("good" cholesterol), but it does not lead to the formation of abnormal lipoproteins like LpX. * **Polyunsaturated Fatty Acids (PUFAs):** PUFAs are generally cardioprotective and help in lowering LDL levels. They do not trigger the pathological lipid aggregation seen in cholestasis. **High-Yield Clinical Pearls for NEET-PG:** * **Composition:** LpX contains roughly 90% lipid (mostly free cholesterol and lecithin) and only 10% protein (mainly Albumin and Apo-C). * **Electrophoresis:** On agar gel electrophoresis, LpX exhibits **abnormal cathodic migration** (moves toward the cathode), which distinguishes it from other lipoproteins. * **LCAT Deficiency:** LpX is also a hallmark of Familial LCAT deficiency because the inability to esterify cholesterol leads to its accumulation in the free form, similar to the mechanism in cholestasis.

Q: A 50-year-old male patient with a history of hypertension, currently on medication, presents for a routine checkup. Laboratory investigations show plasma cholesterol levels of 5.8 mmol/L and random blood sugar of 180 mg/dL. The physician advised dietary restrictions to prevent arteriosclerosis. Which of the following factors does NOT contribute to the development of arteriosclerosis?

Low LDL:HDL cholesterol ratio. **Explanation** The correct answer is **D. Low LDL:HDL cholesterol ratio.** **1. Why the correct answer is right:** Arteriosclerosis is driven by the accumulation of lipids in the arterial walls. To assess cardiovascular risk, the **LDL:HDL ratio** is a critical predictor. * **LDL (Low-Density Lipoprotein)** is "bad cholesterol" because it transports cholesterol from the liver to the tissues (pro-atherogenic). * **HDL (High-Density Lipoprotein)** is "good cholesterol" because it promotes reverse cholesterol transport, moving lipids from the tissues back to the liver (anti-atherogenic). A **low ratio** indicates either low LDL or high HDL levels, both of which are **protective** against arteriosclerosis. Conversely, a high ratio is a major risk factor. **2. Why the other options are wrong:** * **A & B (High plasma/dietary cholesterol):** Elevated circulating cholesterol (hypercholesterolemia), often driven by diets rich in saturated fats and cholesterol, leads to endothelial injury and the formation of foam cells, the hallmark of atherosclerotic plaques. * **C (Elevated blood triacylglycerol):** Hypertriglyceridemia is an independent risk factor for cardiovascular disease. High triglycerides often correlate with low HDL levels and the presence of small, dense LDL particles, which are highly prone to oxidation and plaque formation. **3. NEET-PG High-Yield Pearls:** * **Atherogenic Index:** The ratio of Total Cholesterol/HDL (>4.5) or LDL/HDL (>3.5) is considered a significant risk factor for Ischemic Heart Disease (IHD). * **Protective Factors:** HDL levels >60 mg/dL are considered cardioprotective. * **Dietary Goal:** For prevention of atherosclerosis, saturated fat intake should be <7% of total energy, and dietary cholesterol should be <200 mg/day. * **Rule of Thumb:** "LDL is **L**ethal; HDL is **H**ealthy."

Question 1

A child presented with altered sensorium and icterus three days after a viral illness for which he was treated with aspirin. What is the underlying biochemical defect?

Accepted Answer

Beta oxidation of fatty acids

Answer

Glucose-6-phosphatase deficiency

Answer

Pyruvate dehydrogenase deficiency

Answer

Urea cycle defect

Question 2

Hypertriglyceridemia is not a feature of which of the following conditions?

Accepted Answer

Alcoholism

Answer

Obesity

Answer

Diabetes mellitus

Answer

Pregnancy

Question 3

Which one of the following is of highest predictive value in the morbidity of coronary heart disease?

Accepted Answer

Apolipoprotein B

Answer

Lipoprotein A

Answer

Apolipoprotein A

Answer

Low density lipoprotein

Question 4

All of the following statements about fatty acid synthesis are true, except:

Accepted Answer

Palmitoleic acid is the end product

Answer

Occurs in cytosol

Answer

Citrate shuttle is required

Answer

Acetyl CoA is the immediate substrate

Question 5

Eicosapentaenoic acid is present in which of the following?

Accepted Answer

Fish oil

Answer

Soybean oil

Answer

Corn oil

Answer

Safflower oil

Question 6

Which of the following uses ketone bodies, except?

Accepted Answer

Hepatocytes

Answer

Brain

Answer

RBCs

Answer

Skeletal muscles

Question 7

Hepatosplenomegaly with foam cells is characteristically seen in a lysosomal disorder. This disorder is due to the deficiency of which enzyme?

Accepted Answer

Sphingomyelinase

Answer

Hexosaminidase

Answer

Beta-galactosidase

Answer

Beta-glucosidase

Question 8

In the well-fed state, what inhibits the activity of Carnitine Palmitoyl Transferase-1 located in the outer mitochondrial membrane?

Accepted Answer

Malonyl-CoA

Answer

Glucose

Answer

Acetyl-CoA

Answer

Pyruvate

Question 9

Lipoprotein X is most likely to be seen with which of the following conditions?

Accepted Answer

Cholestasis

Answer

Gilbert syndrome

Answer

Increased intake of trans fatty acids

Answer

Increased intake of polyunsaturated fatty acids

Question 10

A 50-year-old male patient with a history of hypertension, currently on medication, presents for a routine checkup. Laboratory investigations show plasma cholesterol levels of 5.8 mmol/L and random blood sugar of 180 mg/dL. The physician advised dietary restrictions to prevent arteriosclerosis. Which of the following factors does NOT contribute to the development of arteriosclerosis?

Accepted Answer

Low LDL:HDL cholesterol ratio

Answer

High plasma cholesterol levels

Answer

Diets high in cholesterol

Answer

Elevated blood triacylglycerol

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?